This agenda is from the 2018 show. The 2019 agenda is to be announced closer to the show.
Wednesday 6th June
Thursday 7th June
11.00 - 11.30
Michiel van den Brekel
In this seminar I will give an update on the possibilities of both vocal and pulmonary rehabilitation after total laryngectomy. Recent developments in voice rehabilitation, as well as adverse events and the management of complications will be discussed.
11.45 - 12.15
Mavis Nye BCaH
A patients Story of Asbestos and mesothelioma
12.30 - 13.00
Ultra-small liposomes of 30nm in size give rise to unknown pharmacological effects. Talidox (Targeted Liposomal Doxorubicin) accumulates chemotherapeutic drug in cancer tissue and minimizes its side effects. Using the nano-shuttle, near-infrared dye is specifically transported to tumors and can assist during fluorescence-guided surgery. Talineuren (Targeted Liposomal Neuroregenerator) delivers neuroprotective GM1 ganglioside to the brain after oral intake, thereby e.g. elevating dopamine levels in the striatum in Parkinson models of disease.
13.15 - 13.45
Dr Ndaba Mazibuko
Care Oncology Clinic (COC) has been set up to enable the use of off-label drugs by Physicians to treat cancer patients as an adjunct to their standard of care. COC has developed a protocol which comprises a combination of four generic metabolic modulating medicines. These medicines have excellent safety profiles and well-established anti-cancer effects in pluralistic peer-review literature. COC’s analysis seeks to contribute to this emerging data.
14.00 - 14.30
Dr Mohamed Torky
The seminar will present the preliminary results of a study included patients with peripheral lung lesions suspicious for lung cancer. Trans-bronchial biopsies were performed using forceps and crio-probe under guidance of radial endobronchial ultrasound (Radial EBUS) for diagnosis of the included lesions. The results were promising with high yield of diagnostic value and low rate of complications. The study was presented at European respiratory society congress, Milan 2017.
14.45 - 15.15
Professor Alex Mirnezami
Biomarkers of Epithelial to Mesenchymal Transition and their clinical relevance in colorectal cancer
An important event in the metastatic cascade is epithelial to mesenchymal transition (EMT), a reversible phenotypic switch, which endows malignant epithelial cells with the capacity to break free from one another and invade the surrounding stroma. Our understanding of EMT has been significantly improved by the characterization of miRNAs and the mission critical transcription factors that influence the signalling pathways and downstream events that define EMT on a molecular level. This seminar describes the latest findings in this field and presents the latest results from our group highlighting the key prognostic and predictive potential of biomarkers of EMT.